Remove plaque that impedes blood flow and circulation in the legs with the TurboHawk™ peripheral plaque excision system. Choose from a High Efficiency Cutter model that can tackle calcified plaque or a Smooth Cutter model that can treat mild-to-moderately calcified lesions. Proven clinically in the landmark DEFINITIVE LE trial, the study found that diabetic PAD patients fared as well as nondiabetics and that claudicants had high patency at 12 months when treated with plaque excision technology.1Product Details
Preserve the native vessel and keep future treatment options open for PAD patients when you treat with the SilverHawk™ peripheral plaque excision system. Use the device's directional cutter to shave soft-to-mild plaque, while the nosecone captures the material for removal from the artery. The SilverHawk technology is backed by the landmark DEFINITIVE LE clinical study, which found that PAD patients with critical limb ischemia who were treated with plaque excision experienced a high rate (95%) of limb salvage at 12 months.1Product Details
McKinsey JF, Zeller T, Rocha-Singh KJ, et al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. August 2014;7(8):923–933.